| Drugs by Condition |  |
Respiratory Distress Syndrome Medications
Definition of Respiratory Distress Syndrome: A condition of the newborn marked by dyspnea with cyanosis, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.
Drugs associated with Respiratory Distress Syndrome
The following drugs and medications are in some way related to, or used in the treatment of Respiratory Distress Syndrome. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
||
|---|---|---|---|---|
Survanta (More...) generic name: beractant class: lung surfactants | 0 review(s) | Not rated - Be the first | ||
| Infasurf (More...)generic name: calfactant class: lung surfactants | 0 review(s) | Not rated - Be the first | ||
| Survanta Intratracheal (More...)generic name: beractant class: lung surfactants | 0 review(s) | Not rated - Be the first | ||
Respiratory Distress Syndrome Medications in the Pipeline
- October 2, 2009 - Discovery Labs and FDA Establish Path for Potential Surfaxin Approval
- September 11, 2009 - Discovery Labs and FDA to Meet On September 29, 2009 to Discuss Potential Path for Surfaxin Approval
- July 2, 2009 - Discovery Labs Reports On Surfaxin End of Review Meeting With FDA
- May 12, 2009 - Discovery Labs and FDA to Meet On June 2, 2009 to Discuss Surfaxin Complete Response Letter
- November 10, 2008 - FDA Establishes Target Action Date of April 17, 2009 for Potential Approval of Discovery Labs' Surfaxin
- October 20, 2008 - Discovery Labs Submits Complete Response to May 2008 FDA Approvable Letter for Surfaxin for RDS
- September 24, 2008 - Discovery Labs Reports Technical Achievements Towards Gaining FDA Approval of Surfaxin
- August 6, 2008 - Discovery Labs Reports Progress in Responding to Surfaxin FDA Approvable Letter
- June 19, 2008 - Discovery Labs and FDA Meet to Clarify Limited Items in Surfaxin Approvable Letter
- May 29, 2008 - Discovery Labs and FDA to Meet On June 18, 2008 to Clarify Limited Items in Surfaxin Approvable Letter
- May 5, 2008 - Discovery Labs Provides Guidance On FDA Approvable Letter for Surfaxin for RDS
- May 2, 2008 - Discovery Labs Receives An Approvable Letter From FDA for Surfaxin for RDS
- November 16, 2007 - Discovery Labs' Response to Surfaxin Approvable Letter Deemed Complete by FDA
- November 1, 2007 - Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants
- October 1, 2007 - Surfaxin Process Validation Batches Achieve Stability Milestone to Enable Filing of Response to FDA Approvable Letter
- August 2, 2007 - Discovery Labs Provides Update On Progress for Surfaxin for RDS
- January 22, 2007 - Discovery Labs and FDA Reach Clarity On Path Towards Surfaxin RDS Approval
- September 28, 2006 - Discovery Labs Updates Progress On Manufacturing Remediation and Surfaxin FDA Regulatory Matters
- April 5, 2006 - Discovery Labs Receives Second Approvable Letter From FDA for Surfaxin for RDS
- October 21, 2005 - FDA Accepts Discovery Labs' Complete Response to Approvable Letter for Surfaxin
- August 19, 2005 - Discovery Labs Provides Update on Status of Response to FDA Approvable Letter for Surfaxin
- August 15, 2005 - Discovery Labs Provides Status of Previously Submitted Response to FDA Approvable Letter for Surfaxin
- July 29, 2005 - Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants
- February 14, 2005 - Discovery Labs Receives Approvable Letter from FDA for Surfaxin for Respiratory Distress Syndrome in Premature Infants
- June 15, 2004 - Discovery Laboratories Announces FDA Acceptance of Surfaxin New Drug Application
- April 14, 2004 - Discovery Laboratories Files New Drug Application with the FDA to Market Surfaxin for the Prevention of Respiratory Distress Syndrome in Premature Infants
Latest Respiratory Distress Syndrome Blog Post
Additional Steroid Dose May Help Preemies
THURSDAY, Jan. 29 -- Giving a second dose of steroids to babies still in the womb can reduce their post-birth respiratory problems and does not seem to affect their growth the way multiple courses can, new research shows.
In babies born before 34 weeks,...
View all Respiratory Distress Syndrome blog posts.
